Current experience with treatment of prognostically unfavorable acute myeloid leukemias with CPX-351 at the Institute of Hematology and Blood Transfusion

Abstract

Therapeutic agent CPX-351, Vyxeos liposomal, is a newly approved drug intended for therapy of high-risk subtypes of acute myeloid leukemia (AML) sucha as AML arising from antecendent myelodsplastic syndrome or in connection with previous anticancer therapy. In the Czech Republic CPX-351 is reimbursed for patients aged 60 and over with above-mentioned AML subtypes. The following paper describes in its introduction the indication and dosage schedule of CPX-351, its mechanism of action and also briefly mentions the therapeutic results and safety profile of CPX-351 accoording to the product registration study. In the main part, the article describes current clinical experience with CPX-351 obtained since 2022 at the UHKT Prague and analyzes in detail case reports of two patients treated at the UHKT in last months. CPX-351 therapy represents, according to UHKTs experience so far, a relatively effective option for the treatment of high-risk AML in which treatment with standard chemotherapy often fails.